UGT1A1*6 and UGT1A1*28 polymorphisms are correlated with irinotecan-induced toxicity: A meta-analysis
Published 2018 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
UGT1A1*6 and UGT1A1*28 polymorphisms are correlated with irinotecan-induced toxicity: A meta-analysis
Authors
Keywords
-
Journal
Asia-Pacific Journal of Clinical Oncology
Volume -, Issue -, Pages -
Publisher
Wiley
Online
2018-06-22
DOI
10.1111/ajco.13028
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Efficacy and toxicity of different concurrent chemoradiotherapy regimens in the treatment of advanced cervical cancer
- (2017) Zhan-Zhao Fu et al. MEDICINE
- A multicenter phase II study of personalized FOLFIRI-cetuximab for safe dose intensification
- (2017) Michèle Boisdron-Celle et al. SEMINARS IN ONCOLOGY
- Relationship between UGT1A1*6/*28 gene polymorphisms and the efficacy and toxicity of irinotecan-based chemotherapy
- (2017) Yu Bai et al. OncoTargets and Therapy
- Impact of UGT1A1 genotype upon toxicities of combination with low-dose irinotecan plus platinum
- (2016) Masashi Takano et al. Asia-Pacific Journal of Clinical Oncology
- Cancer statistics in China, 2015
- (2016) Wanqing Chen et al. CA-A CANCER JOURNAL FOR CLINICIANS
- UGT1A1 gene polymorphism is associated with toxicity and clinical efficacy of irinotecan-based chemotherapy in patients with advanced colorectal cancer
- (2016) Chunlei Xu et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Correlation of UGT1A1 * 28 and * 6 polymorphisms with irinotecan-induced neutropenia in Thai colorectal cancer patients
- (2016) Chalirmporn Atasilp et al. Drug Metabolism and Pharmacokinetics
- Effects of UGT1A1*6, UGT1A1*28, and ABCB1-3435C>T polymorphisms on irinotecaninduced toxicity in Chinese cancer patients
- (2016) Liang Yan et al. INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS
- Phase I study of irinotecan for previously treated lung cancer patients with theUGT1A1*28or*6polymorphism: Results of the Lung Oncology Group in Kyushu (LOGIK1004A)
- (2016) Minoru Fukuda et al. Thoracic Cancer
- Prospective study of theUGT1A1*27gene polymorphism during irinotecan therapy in patients with lung cancer: Results of Lung Oncology Group in Kyusyu (LOGIK1004B)
- (2016) Minoru Fukuda et al. Thoracic Cancer
- An internally and externally validated nomogram for predicting the risk of irinotecan-induced severe neutropenia in advanced colorectal cancer patients
- (2015) W Ichikawa et al. BRITISH JOURNAL OF CANCER
- UGT1A1genotype and irinotecan therapy: general review and implementation in routine practice
- (2015) Marie-Christine Etienne-Grimaldi et al. FUNDAMENTAL & CLINICAL PHARMACOLOGY
- Correlation of UGT1A1 and ERCC1 gene polymorphisms with the outcome of combined irinotecan plus cisplatin treatment in recurrent ovarian cancer
- (2015) Q. Xu et al. GENETICS AND MOLECULAR RESEARCH
- High-Dose FOLFIRI plus Bevacizumab in the Treatment of Metastatic Colorectal Cancer Patients with Two Different UGT1A1 Genotypes: FFCD 0504 Study
- (2015) S. Manfredi et al. MOLECULAR CANCER THERAPEUTICS
- The relationship between UGT1A1 gene polymorphism and irinotecan effect on extensive-stage small-cell lung cancer
- (2015) Xiaoguang Xiao et al. OncoTargets and Therapy
- Cisplatin combined with irinotecan or etoposide for untreated extensive-stage small cell lung cancer: A multicenter randomized controlled clinical trial
- (2015) Yuankai Shi et al. Thoracic Cancer
- UGT1A1*6 polymorphisms are correlated with irinotecan-induced toxicity: a system review and meta-analysis in Asians
- (2014) Lei Cheng et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Development of Pyrosequencing Method for Detection ofUGT1A1Polymorphisms in Thai Colorectal Cancers
- (2014) Chonlaphat Sukasem et al. JOURNAL OF CLINICAL LABORATORY ANALYSIS
- Dose-Finding and Pharmacokinetic Study to Optimize the Dosing of Irinotecan According to theUGT1A1Genotype of Patients With Cancer
- (2014) Federico Innocenti et al. JOURNAL OF CLINICAL ONCOLOGY
- The effect of the UGT1A1*28 allele on survival after irinotecan-based chemotherapy: a collaborative meta-analysis
- (2014) M M Dias et al. PHARMACOGENOMICS JOURNAL
- The association of UGT1A1*6 and UGT1A1*28 with irinotecan-induced neutropenia in Asians: a meta-analysis
- (2013) Yi-Jing Chen et al. BIOMARKERS
- UGT1A1 genotype-guided phase I study of irinotecan, oxaliplatin, and capecitabine
- (2013) Matthew P. Goetz et al. INVESTIGATIONAL NEW DRUGS
- Associations between UGT1A1*6/*28 polymorphisms and irinotecan-induced severe toxicity in Chinese gastric or esophageal cancer patients
- (2013) Jing Gao et al. MEDICAL ONCOLOGY
- Association of UGT1A1*28 polymorphisms with irinotecan-induced toxicities in colorectal cancer: a meta-analysis in Caucasians
- (2013) X Liu et al. PHARMACOGENOMICS JOURNAL
- Evaluation of the Endorsement of the Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) Statement on the Quality of Published Systematic Review and Meta-Analyses
- (2013) Nikola Panic et al. PLoS One
- Polymorphisms of the UDP-Glucuronosyl Transferase 1A Genes Are Associated with Adverse Events in Cancer Patients Receiving Irinotecan-Based Chemotherapy
- (2013) Kazuyuki Inoue et al. TOHOKU JOURNAL OF EXPERIMENTAL MEDICINE
- Phase II and UGT1A1 genotype study of irinotecan dose escalation as salvage therapy for advanced gastric cancer
- (2012) J-C Jo et al. BRITISH JOURNAL OF CANCER
- The value of genetic polymorphisms to predict toxicity in metastatic colorectal patients with irinotecan-based regimens
- (2012) M. J. Lamas et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- UGT1A1predicts outcome in colorectal cancer treated with irinotecan and fluorouracil
- (2012) Yan Wang WORLD JOURNAL OF GASTROENTEROLOGY
- A genotype-directed phase I–IV dose-finding study of irinotecan in combination with fluorouracil/leucovorin as first-line treatment in advanced colorectal cancer
- (2011) E Marcuello et al. BRITISH JOURNAL OF CANCER
- Clinical implications of UGT1A1*28 genotype testing in colorectal cancer patients
- (2011) Katerina Shulman et al. CANCER
- Genotype-directed, dose-finding study of irinotecan in cancer patients with UGT1A1*28 and/or UGT1A1*6 polymorphisms
- (2011) Taroh Satoh et al. CANCER SCIENCE
- Pharmacokinetic and Pharmacogenetic Predictive Markers of Irinotecan Activity and Toxicity
- (2011) Antonello Di Paolo et al. CURRENT DRUG METABOLISM
- Prospective Phase II Study of FOLFIRI for mCRC in Japan, Including the Analysis of UGT1A1*28/*6 Polymorphisms
- (2011) Y. Okuyama et al. JAPANESE JOURNAL OF CLINICAL ONCOLOGY
- Phase II study of a triplet regimen of S-1 combined with irinotecan and oxaliplatin in patients with metastatic gastric cancer: clinical and pharmacogenetic results
- (2010) S. R. Park et al. ANNALS OF ONCOLOGY
- UGT1A and TYMS genetic variants predict toxicity and response of colorectal cancer patients treated with first-line irinotecan and fluorouracil combination therapy
- (2010) E Martinez-Balibrea et al. BRITISH JOURNAL OF CANCER
- Dose-Dependent Association between UGT1A1*28 Genotype and Irinotecan-Induced Neutropenia: Low Doses Also Increase Risk
- (2010) Z.-Y. Hu et al. CLINICAL CANCER RESEARCH
- Pharmacogenetic Predictors of Adverse Events and Response to Chemotherapy in Metastatic Colorectal Cancer: Results From North American Gastrointestinal Intergroup Trial N9741
- (2010) Howard L. McLeod et al. JOURNAL OF CLINICAL ONCOLOGY
- The UGT1A1*28 Genotype and the Toxicity of Low-Dose Irinotecan in Patients With Advanced Lung Cancer
- (2010) Tomohide Sugiyama et al. ONCOLOGY RESEARCH
- Prediction of irinotecan and 5-fluorouracil toxicity and response in patients with advanced colorectal cancer
- (2010) B Glimelius et al. PHARMACOGENOMICS JOURNAL
- UGT1A1*6 polymorphism is most predictive of severe neutropenia induced by irinotecan in Japanese cancer patients
- (2009) Masahide Onoue et al. International Journal of Clinical Oncology
- Predictive Role of the UGT1A1, UGT1A7, and UGT1A9 Genetic Variants and Their Haplotypes on the Outcome of Metastatic Colorectal Cancer Patients Treated With Fluorouracil, Leucovorin, and Irinotecan
- (2009) Erika Cecchin et al. JOURNAL OF CLINICAL ONCOLOGY
- Clinical Significance of UDP-Glucuronosyltransferase 1A1*6 for Toxicities of Combination Chemotherapy with Irinotecan and Cisplatin in Gynecologic Cancers
- (2009) Masashi Takano et al. ONCOLOGY
- Phase I study of combination chemotherapy with irinotecan hydrochloride and nedaplatin for cervical squamous cell carcinoma: Japanese gynecologic oncology group study
- (2009) Yamamoto ONCOLOGY REPORTS
- UGT1A1*28genotype predicts gastrointestinal toxicity in patients treated with intermediate-dose irinotecan
- (2009) Roberta Ferraldeschi et al. PHARMACOGENOMICS
- UGT1A1 gene polymorphism: Impact on toxicity and efficacy of irinotecan-based regimens in metastatic colorectal cancer
- (2009) Christoph Schulz et al. WORLD JOURNAL OF GASTROENTEROLOGY
- UGT1A1*28 genotype and irinotecan dosage in patients with metastatic colorectal cancer: a Dutch Colorectal Cancer Group study
- (2008) D M Kweekel et al. BRITISH JOURNAL OF CANCER
- Irinotecan-induced mucositis is associated with changes in intestinal mucins
- (2008) Andrea M. Stringer et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Irinotecan Pharmacogenetics: Influence of Pharmacodynamic Genes
- (2008) J. M. Hoskins et al. CLINICAL CANCER RESEARCH
- Importance of UDP-glucuronosyltransferase 1A1∗6 for irinotecan toxicities in Japanese cancer patients
- (2007) Kimie Sai et al. CANCER LETTERS
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now